Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

ABSTRACT: Two commonly prescribed treatments for opioid addiction are methadone and buprenorphine. Although these drugs show some efficacy in treating opioid dependence, treatment response varies among individuals. It is likely that genetic factors have a role in determining treatment outcome. This study analyses the pharmacogenetic association of six polymorphisms in OPRD1, the gene encoding the delta-opioid receptor, on treatment outcome in 582 opioid addicted European Americans randomized to either methadone or buprenorphine/naloxone (Suboxone) over the course of a 24-week open-label clinical trial. Treatment outcome was assessed as the number of missed or opioid-positive urine drug screens over the 24 weeks. In the total sample, no single-nucleotide polymorphisms (SNPs) in OPRD1 were significant

SUBMITTER: Clarke TK 

PROVIDER: S-EPMC3988270 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature